PubRank

Kevin J Barnham

Author PubWeight™ 107.88‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Iron-export ferroxidase activity of β-amyloid precursor protein is inhibited by zinc in Alzheimer's disease. Cell 2010 2.46
2 Rapid restoration of cognition in Alzheimer's transgenic mice with 8-hydroxy quinoline analogs is associated with decreased interstitial Abeta. Neuron 2008 2.30
3 Do current therapeutic anti-Aβ antibodies for Alzheimer's disease engage the target? Acta Neuropathol 2014 2.25
4 Amyloid-beta peptide (Abeta) neurotoxicity is modulated by the rate of peptide aggregation: Abeta dimers and trimers correlate with neurotoxicity. J Neurosci 2008 1.86
5 Copper-dependent inhibition of human cytochrome c oxidase by a dimeric conformer of amyloid-beta1-42. J Neurosci 2005 1.83
6 The redox chemistry of the Alzheimer's disease amyloid beta peptide. Biochim Biophys Acta 2007 1.83
7 18F-THK523: a novel in vivo tau imaging ligand for Alzheimer's disease. Brain 2011 1.67
8 Inhibition of gamma-secretase causes increased secretion of amyloid precursor protein C-terminal fragments in association with exosomes. FASEB J 2008 1.52
9 In vitro characterization of Pittsburgh compound-B binding to Lewy bodies. J Neurosci 2007 1.52
10 Dopamine promotes alpha-synuclein aggregation into SDS-resistant soluble oligomers via a distinct folding pathway. FASEB J 2005 1.51
11 The Caenorhabditis elegans A beta 1-42 model of Alzheimer disease predominantly expresses A beta 3-42. J Biol Chem 2009 1.32
12 Interaction of the molecular chaperone alphaB-crystallin with alpha-synuclein: effects on amyloid fibril formation and chaperone activity. J Mol Biol 2004 1.32
13 Degradation of the Alzheimer disease amyloid beta-peptide by metal-dependent up-regulation of metalloprotease activity. J Biol Chem 2006 1.29
14 Increasing Cu bioavailability inhibits Abeta oligomers and tau phosphorylation. Proc Natl Acad Sci U S A 2009 1.29
15 Metal ions, pH, and cholesterol regulate the interactions of Alzheimer's disease amyloid-beta peptide with membrane lipid. J Biol Chem 2002 1.26
16 Pleomorphic copper coordination by Alzheimer's disease amyloid-beta peptide. J Am Chem Soc 2009 1.22
17 SOD1 (copper/zinc superoxide dismutase) deficiency drives amyloid β protein oligomerization and memory loss in mouse model of Alzheimer disease. J Biol Chem 2011 1.19
18 Formation of a high affinity lipid-binding intermediate during the early aggregation phase of alpha-synuclein. Biochemistry 2008 1.18
19 Amyloid-beta-anti-amyloid-beta complex structure reveals an extended conformation in the immunodominant B-cell epitope. J Mol Biol 2008 1.17
20 Molecular mechanisms for Alzheimer's disease: implications for neuroimaging and therapeutics. J Neurochem 2006 1.16
21 Methylation of the imidazole side chains of the Alzheimer disease amyloid-beta peptide results in abolition of superoxide dismutase-like structures and inhibition of neurotoxicity. J Biol Chem 2005 1.14
22 Amyloid-beta peptide disruption of lipid membranes and the effect of metal ions. J Mol Biol 2005 1.12
23 Copper-mediated amyloid-beta toxicity is associated with an intermolecular histidine bridge. J Biol Chem 2006 1.10
24 Formation of dopamine-mediated alpha-synuclein-soluble oligomers requires methionine oxidation. Free Radic Biol Med 2009 1.09
25 Ferric ions are essential for the biological activity of the hormone glycine-extended gastrin. J Biol Chem 2002 1.09
26 Selective intracellular release of copper and zinc ions from bis(thiosemicarbazonato) complexes reduces levels of Alzheimer disease amyloid-beta peptide. J Biol Chem 2007 1.08
27 The structure of dopamine induced alpha-synuclein oligomers. Eur Biophys J 2010 1.08
28 Concentration dependent Cu2+ induced aggregation and dityrosine formation of the Alzheimer's disease amyloid-beta peptide. Biochemistry 2007 1.06
29 The Alzheimer's therapeutic PBT2 promotes amyloid-β degradation and GSK3 phosphorylation via a metal chaperone activity. J Neurochem 2011 1.06
30 Surface behavior and lipid interaction of Alzheimer beta-amyloid peptide 1-42: a membrane-disrupting peptide. Biophys J 2005 1.05
31 Blood-borne amyloid-beta dimer correlates with clinical markers of Alzheimer's disease. J Neurosci 2010 1.05
32 Alzheimer disease beta-amyloid activity mimics cholesterol oxidase. J Clin Invest 2005 1.04
33 Enhanced toxicity and cellular binding of a modified amyloid beta peptide with a methionine to valine substitution. J Biol Chem 2004 1.04
34 Alanine-2 carbonyl is an oxygen ligand in Cu2+ coordination of Alzheimer's disease amyloid-beta peptide--relevance to N-terminally truncated forms. J Am Chem Soc 2009 1.02
35 Radioiodinated clioquinol as a biomarker for beta-amyloid: Zn complexes in Alzheimer's disease. Aging Cell 2006 1.01
36 Delineating the mechanism of Alzheimer's disease A beta peptide neurotoxicity. Neurochem Res 2007 0.99
37 Stabilization of neurotoxic soluble beta-sheet-rich conformations of the Alzheimer's disease amyloid-beta peptide. Biophys J 2007 0.98
38 Cu2+ binding modes of recombinant alpha-synuclein--insights from EPR spectroscopy. J Am Chem Soc 2008 0.97
39 Oligomers, fact or artefact? SDS-PAGE induces dimerization of β-amyloid in human brain samples. Acta Neuropathol 2013 0.97
40 Utility of an improved model of amyloid-beta (Aβ₁₋₄₂) toxicity in Caenorhabditis elegans for drug screening for Alzheimer's disease. Mol Neurodegener 2012 0.97
41 Dopamine and the dopamine oxidation product 5,6-dihydroxylindole promote distinct on-pathway and off-pathway aggregation of alpha-synuclein in a pH-dependent manner. J Mol Biol 2009 0.96
42 Diacetylbis(N(4)-methylthiosemicarbazonato) copper(II) (CuII(atsm)) protects against peroxynitrite-induced nitrosative damage and prolongs survival in amyotrophic lateral sclerosis mouse model. J Biol Chem 2011 0.96
43 The hypoxia imaging agent CuII(atsm) is neuroprotective and improves motor and cognitive functions in multiple animal models of Parkinson's disease. J Exp Med 2012 0.96
44 Variability in blood-based amyloid-beta assays: the need for consensus on pre-analytical processing. J Alzheimers Dis 2012 0.95
45 Alzheimer's disease & metals: therapeutic opportunities. Br J Pharmacol 2011 0.93
46 Structural studies of the Alzheimer's amyloid precursor protein copper-binding domain reveal how it binds copper ions. J Mol Biol 2006 0.93
47 Therapeutic redistribution of metal ions to treat Alzheimer's disease. Acc Chem Res 2012 0.92
48 Dimeric structures of alpha-synuclein bind preferentially to lipid membranes. Biochim Biophys Acta 2008 0.92
49 Pharmacotherapeutic targets in Alzheimer's disease. J Cell Mol Med 2008 0.91
50 The structure of the amyloid-beta peptide high-affinity copper II binding site in Alzheimer disease. Biophys J 2008 0.90
51 Solid-phase synthesis of homodimeric peptides: preparation of covalently-linked dimers of amyloid beta peptide. Chem Commun (Camb) 2009 0.90
52 Structure of a novel P-superfamily spasmodic conotoxin reveals an inhibitory cystine knot motif. J Biol Chem 2002 0.90
53 The heterogeneous nature of Cu2+ interactions with Alzheimer's amyloid-β peptide. Acc Chem Res 2011 0.89
54 Metal homeostasis in Alzheimer's disease. Expert Rev Neurother 2006 0.89
55 Crystallization and preliminary X-ray diffraction analysis of the Fab fragment of WO2, an antibody specific for the Abeta peptides associated with Alzheimer's disease. Acta Crystallogr Sect F Struct Biol Cryst Commun 2008 0.88
56 Dominant roles of the polybasic proline motif and copper in the PrP23-89-mediated stress protection response. J Cell Sci 2009 0.88
57 Copper binding to the Alzheimer's disease amyloid precursor protein. Eur Biophys J 2007 0.88
58 Restored degradation of the Alzheimer's amyloid-beta peptide by targeting amyloid formation. J Neurochem 2009 0.87
59 Stereospecific interactions are necessary for Alzheimer disease amyloid-β toxicity. Neurobiol Aging 2009 0.87
60 Amyloid-β: the seeds of darkness. Int J Biochem Cell Biol 2011 0.87
61 A novel effect of bismuth ions: selective inhibition of the biological activity of glycine-extended gastrin. J Biol Chem 2003 0.87
62 Anionic phospholipid interactions of the prion protein N terminus are minimally perturbing and not driven solely by the octapeptide repeat domain. J Biol Chem 2010 0.86
63 Copper-dependent inhibition of cytochrome c oxidase by Abeta(1-42) requires reduced methionine at residue 35 of the Abeta peptide. J Neurochem 2006 0.84
64 Model studies of cholesterol and ascorbate oxidation by copper complexes: relevance to Alzheimer's disease beta-amyloid metallochemistry. J Inorg Biochem 2005 0.84
65 Characterizing bathocuproine self-association and subsequent binding to Alzheimer's disease amyloid beta-peptide by NMR. J Pept Sci 2004 0.84
66 Iron inhibits neurotoxicity induced by trace copper and biological reductants. J Biol Inorg Chem 2004 0.84
67 Bis(thiosemicarbazonato) Cu-64 complexes for positron emission tomography imaging of Alzheimer's disease. J Alzheimers Dis 2010 0.84
68 Alpha-synuclein oligomers and fibrils originate in two distinct conformer pools: a small angle X-ray scattering and ensemble optimisation modelling study. Mol Biosyst 2014 0.84
69 Therapeutic treatments for Alzheimer's disease based on metal bioavailability. Drug News Perspect 2006 0.83
70 Differential modulation of Alzheimer's disease amyloid beta-peptide accumulation by diverse classes of metal ligands. Biochem J 2007 0.83
71 Methionine regulates copper/hydrogen peroxide oxidation products of Abeta. J Pept Sci 2005 0.83
72 Conservation of a glycine-rich region in the prion protein is required for uptake of prion infectivity. J Biol Chem 2010 0.83
73 Diagnostic imaging agents for Alzheimer's disease: copper radiopharmaceuticals that target Aβ plaques. J Am Chem Soc 2013 0.82
74 Progress towards a consensus on biomarkers for Alzheimer's disease: a review of peripheral analytes. Biomark Med 2013 0.82
75 Cu2+-induced modification of the kinetics of A beta(1-42) channels. Am J Physiol Cell Physiol 2003 0.81
76 Metal catalyzed oxidation of tyrosine residues by different oxidation systems of copper/hydrogen peroxide. J Inorg Biochem 2004 0.81
77 Increased ATP-binding cassette transporter A1 expression in Alzheimer's disease hippocampal neurons. J Alzheimers Dis 2010 0.81
78 Near-infrared fluorescence imaging of apoptotic neuronal cell death in a live animal model of prion disease. ACS Chem Neurosci 2010 0.81
79 Cholesterol and Clioquinol modulation of A beta(1-42) interaction with phospholipid bilayers and metals. Biochim Biophys Acta 2007 0.81
80 Activation of epidermal growth factor receptor by metal-ligand complexes decreases levels of extracellular amyloid beta peptide. Int J Biochem Cell Biol 2008 0.81
81 Therapeutic effects of CuII(atsm) in the SOD1-G37R mouse model of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener 2013 0.81
82 Sustained activation of glial cell epidermal growth factor receptor by bis(thiosemicarbazonato) metal complexes is associated with inhibition of protein tyrosine phosphatase activity. J Med Chem 2009 0.81
83 Dimerisation of N-acetyl-L-tyrosine ethyl ester and Abeta peptides via formation of dityrosine. Free Radic Res 2006 0.81
84 Alzheimer's Aβ peptides with disease-associated N-terminal modifications: influence of isomerisation, truncation and mutation on Cu2+ coordination. PLoS One 2010 0.80
85 Neurotoxic species in prion disease: a role for PrP isoforms? J Neurochem 2007 0.80
86 Membrane interactions and the effect of metal ions of the amyloidogenic fragment Abeta(25-35) in comparison to Abeta(1-42). Biochim Biophys Acta 2007 0.80
87 Optical imaging detects apoptosis in the brain and peripheral organs of prion-infected mice. J Neuropathol Exp Neurol 2011 0.79
88 Neurotoxicity in Alzheimer's disease: is covalently crosslinked A beta responsible? Eur Biophys J 2007 0.79
89 The amyloid precursor protein copper binding domain histidine residues 149 and 151 mediate APP stability and metabolism. J Biol Chem 2012 0.78
90 Metals, membranes, and amyloid-β oligomers: key pieces in the Alzheimer's disease puzzle? J Alzheimers Dis 2013 0.78
91 A copper radiopharmaceutical for diagnostic imaging of Alzheimer's disease: a bis(thiosemicarbazonato)copper(II) complex that binds to amyloid-beta plaques. Chem Commun (Camb) 2010 0.78
92 Copper and zinc bis(thiosemicarbazonato) complexes with a fluorescent tag: synthesis, radiolabelling with copper-64, cell uptake and fluorescence studies. J Biol Inorg Chem 2009 0.78
93 Pathogenic mutations within the hydrophobic domain of the prion protein lead to the formation of protease-sensitive prion species with increased lethality. J Virol 2013 0.78
94 Anti-Aβ antibody target engagement: a response to Siemers et al. Acta Neuropathol 2014 0.77
95 Mixed ligand Cu2+ complexes of a model therapeutic with Alzheimer's amyloid-β peptide and monoamine neurotransmitters. Inorg Chem 2013 0.77
96 Cell cycle arrest in cultured neuroblastoma cells exposed to a bis(thiosemicarbazonato) metal complex. Biometals 2010 0.77
97 Histidine 14 modulates membrane binding and neurotoxicity of the Alzheimer's disease amyloid-beta peptide. J Alzheimers Dis 2010 0.77
98 Alzheimer's disease and metals: a review of the involvement of cellular membrane receptors in metallosignalling. Int J Alzheimers Dis 2011 0.77
99 Development of a platinum complex as an anti-amyloid agent for the therapy of Alzheimer's disease. Angew Chem Int Ed Engl 2013 0.77
100 Structural insights into the interaction of platinum-based inhibitors with the Alzheimer's disease amyloid-β peptide. Chem Commun (Camb) 2013 0.77
101 Structure and activity of D-Pro14 melittin. J Protein Chem 2002 0.76
102 Biological activity and ferric ion binding of fragments of glycine-extended gastrin. Biochemistry 2004 0.76
103 Modulating metals as a therapeutic strategy for Alzheimer's disease. Future Med Chem 2012 0.76
104 Crystallization and preliminary crystallographic studies of the copper-binding domain of the amyloid precursor protein of Alzheimer's disease. Acta Crystallogr Sect F Struct Biol Cryst Commun 2004 0.76
105 Guanidine hydrochloride denaturation of dopamine-induced α-synuclein oligomers: a small-angle X-ray scattering study. Proteins 2013 0.76
106 Increasing the predictive accuracy of amyloid-β blood-borne biomarkers in Alzheimer's disease. J Alzheimers Dis 2011 0.76
107 Electron paramagnetic resonance characterization of the copper-resistance protein PcoC from Escherichia coli. J Biol Inorg Chem 2008 0.76
108 Generation of soluble oligomeric beta-amyloid species via copper catalyzed oxidation with implications for Alzheimer's disease: a DFT study. J Mol Model 2009 0.76
109 Small angle X-ray scattering analysis of Cu(2+)-induced oligomers of the Alzheimer's amyloid β peptide. Metallomics 2015 0.75
110 C-terminal peptides modelling constitutive PrPC processing demonstrate ameliorated toxicity predisposition consequent to α-cleavage. Biochem J 2014 0.75
111 Synthesis of Oxorhenium(V) and Oxotechnetium(V) Complexes That Bind to Amyloid-β Plaques. Inorg Chem 2016 0.75
112 Quantification of copper binding to amyloid precursor protein domain 2 and its Caenorhabditis elegans ortholog. Implications for biological function. Metallomics 2014 0.75
113 Biophysical investigations of the prion protein using electron paramagnetic resonance. Methods Mol Biol 2008 0.75
114 Rhenium and technetium complexes that bind to amyloid-β plaques. Dalton Trans 2015 0.75
115 Synthesis of 2-pyridyl-benzimidazole iridium(III), ruthenium(II), and platinum(II) complexes. study of the activity as inhibitors of amyloid-β aggregation and neurotoxicity evaluation. Inorg Chem 2014 0.75
116 Analysis of Abeta interactions using ProteinChip technology. Methods Mol Biol 2008 0.75